Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

533
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
533
Cancer Survival Analysis01:21

Cancer Survival Analysis

629
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
629
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

536
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
536
Hazard Ratio01:12

Hazard Ratio

549
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
549
The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

965
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
965
Actuarial Approach01:20

Actuarial Approach

276
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
276

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robust Permutation Test of Intraclass Correlation Coefficient for Assessing Agreement.

Cancers·2025
Same author

Optimizing One-Sample Tests for Proportions in Single- and Two-Stage Oncology Trials.

Cancers·2025
Same author

Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints.

Statistical methods in medical research·2025
Same author

Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer.

Research square·2024
Same author

Multiomics integrated analysis and experimental validation identify TLR4 and ALOX5 as oxidative stress-related biomarkers in intracranial aneurysms.

Journal of neuroinflammation·2024
Same author

Asymmetric catalytic concise synthesis of 3-(3-indolomethyl)-oxindoles for the construction of trigolute analogs.

Chemical communications (Cambridge, England)·2024
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
Same journal

Neoadjuvant Immunotherapy-Based Treatment Versus Chemotherapy Alone in Resectable Locally Advanced dMMR/MSI-H Gastric Cancer: A Real-World Study with Meta-Analysis.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

An Alternative Treatment Effect Measure for Time-to-Event Oncology Randomized Trials.

Alan D Hutson1, Han Yu1

  • 1Roswell Park Comprehensive Cancer Center, Department of Biostatistics and Bioinformatics, Elm and Carlton Streets, Buffalo, NY 14623, USA.

Cancers
|December 11, 2025
PubMed
Summary
This summary is machine-generated.

A new endpoint, the univariate martingale residual (UMR), offers an assumption-free way to analyze oncology trial survival data. This method provides robust and exact inference, outperforming traditional survival analysis in complex scenarios.

Keywords:
martingale residualspermutation testproportional hazardsrandomization testsurvival analysis

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.1K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K

Related Experiment Videos

Last Updated: Jan 9, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.1K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Survival Analysis

Background:

  • Time-to-event endpoints like Overall Survival (OS) are crucial in phase III oncology trials.
  • Current methods (Cox models, log-rank tests) rely on proportional hazards and large-sample assumptions.
  • These standard methods can be unreliable with heavy censoring or non-proportional hazards.

Purpose of the Study:

  • Introduce the univariate martingale residual (UMR) as a novel endpoint and summary measure.
  • Develop an exact inference framework using randomization testing for UMR.
  • Provide a robust alternative to traditional survival analysis in oncology trials.

Main Methods:

  • The UMR quantifies the difference between observed and expected events per subject.
  • Average UMRs per arm provide an absolute measure of excess events.
  • A randomization-based testing framework computes exact p-values, bypassing proportional hazards and asymptotic assumptions.

Main Results:

  • UMRs provided stable and interpretable summaries under heavy censoring and non-proportional hazards.
  • The UMR-based randomization test maintained Type I error control.
  • The UMR test was competitive or more powerful than the log-rank test when proportional hazards were violated.

Conclusions:

  • The UMR offers an intuitive, assumption-free summary of treatment effects.
  • UMR supports exact inference, crucial for reliable clinical trial results.
  • UMR is a practical and robust alternative for phase III oncology trials, especially in complex survival situations.